Compare · ABBV vs EVMN
ABBV vs EVMN
Side-by-side comparison of AbbVie Inc. (ABBV) and Evommune Inc. (EVMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and EVMN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $458.24B, about 1119.9x EVMN ($409.2M).
- Over the past year, ABBV is up 37.6% and EVMN is down 42.5% - ABBV leads by 80.0 points.
- ABBV has been more active in the news (5 items in the past 4 weeks vs 3 for EVMN).
- ABBV has more recent analyst coverage (25 ratings vs 12 for EVMN).
- Company
- AbbVie Inc.
- Evommune Inc.
- Price
- $259.26+0.91%
- $11.37+0.35%
- Market cap
- $458.24B
- $409.2M
- 1M return
- +10.36%
- -51.66%
- 1Y return
- +37.55%
- -42.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- 2025
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 12
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest EVMN
- SEC Form SCHEDULE 13G filed by Evommune Inc.
- Chief Financial Officer Carver Kyle bought $13,260 worth of shares (1,000 units at $13.26), increasing direct ownership by 2% to 60,335 units (SEC Form 4)
- Director Kirsch Arthur S bought $133,000 worth of shares (10,000 units at $13.30) (SEC Form 4)
- Evommune downgraded by H.C. Wainwright
- Evommune downgraded by William Blair
- SEC Form 424B3 filed by Evommune Inc.
- Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
- Chief of Dev. Operations Drew Janice Suzann exercised 20,000 shares at a strike of $3.15 and sold $452,600 worth of shares (20,000 units at $22.63) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Patel Jeegar Pravinkumar exercised 1,488 shares at a strike of $3.84 and sold $33,480 worth of shares (1,488 units at $22.50) as part of a pre-agreed trading plan (SEC Form 4)